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Prioritizing multiple therapeutic targets in parallel
using automated DNA-encoded library screening
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The identiﬁcation and prioritization of chemically tractable therapeutic targets is a signiﬁcant
challenge in the discovery of new medicines. We have developed a novel method that rapidly
screens multiple proteins in parallel using DNA-encoded library technology (ELT). Initial
efforts were focused on the efﬁcient discovery of antibacterial leads against 119 targets from
Acinetobacter baumannii and Staphylococcus aureus. The success of this effort led to the
hypothesis that the relative number of ELT binders alone could be used to assess the
ligandability of large sets of proteins. This concept was further explored by screening 42
targets from Mycobacterium tuberculosis. Active chemical series for six targets from our initial
effort as well as three chemotypes for DHFR from M. tuberculosis are reported. The ﬁndings
demonstrate that parallel ELT selections can be used to assess ligandability and highlight
opportunities for successful lead and tool discovery.
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D
rug discovery and development is an extremely challen-
ging, lengthy and expensive endeavour with an unsus-
tainable success rate1,2. Understanding the ligandability of
a target protein remains a central challenge for early small
molecule drug discovery programmes3. An integrated lead
discovery approach often employs biochemical target-based
screening, cellular screening, phenotypic screening or a
combination of methods. In most cases, a biochemical target-
based approach is chosen to search for early lead molecules4. This
approach requires extensive reagent generation, assay
development, lead identiﬁcation and optimization efforts, and
can amount to years of invested time and millions of dollars in
expense. The approach only interrogates a tiny fraction of the
essential and druggable proteome and often results in failure after
considerable investment. The alternative phenotypic and cellular
screening methods probe multiple targets but often require target
deconvolution efforts to support lead optimization as well as
signiﬁcant resource and technology investments to execute5,6.
The antibacterial therapeutic area is particularly challenging, with
the number of approved drugs steadily declining since 1980.
Multiple factors have contributed to the lack of success, including
the emergence of resistance, challenges in designing cell
penetration properties into an antibacterial agent, a focus on
genes essential for growth in rich media (only 7% in Escherichia
coli) and a general lack of tools to understand the complex
biology of host–pathogen interactions7–9. In addition to the many
uncharacterized bacterial targets, 75% of protein research into
human targets still focuses on only 10% of the proteins known
before the human genome mapping10. A platform to prioritize
this wider scope of targets based on ligandability and the rapid
identiﬁcation of lead and tool molecules for these proteins will aid
in a deeper understanding of biology and the discovery of the
next generation of therapeutics.
A variety of academic and pharmaceutical research has been
directed towards addressing the need for understanding chemical
tractability over the past decade and both experimental and
computational strategies have been reported11–13. As described
elsewhere, chemical tractability or ligandability is the ability of a
protein to bind chemical matter, whereas druggability describes
the possibility of discovering a molecule for the target that will
modulate the disease state3. A technique to characterize small
molecule ‘hot spots’ on proteins was reported by Hajduk et al.14,
where the relationship between ligandability and fragment-
binding measurements with NMR was described. Edfeldt’s more
recent feature highlights the use of fragment technology to probe
the ligandability of 36 targets in the AstraZeneca portfolio over an
8-year period15. Computational methods and docking approaches
have been reported and are highly valueable16,17. These
techniques have helped guide target selection for the past
decade but are often limited by target throughput, experimental
efﬁciency and the prerequisite that structural information is
available.
A relatively recent addition to drug discovery screening is the
use of DNA-encoded chemical libraries (DEL) or encoded library
technology (ELT) to discover small molecule binders to targets of
interest18. First conceptualized in 1992 (ref. 19), various methods
for creating large DNA-encoded combinatorial libraries have
been developed, such as split and pool encoding20, DNA-
templated synthesis21,22 and self-assembling libraries23,24.
Regardless of the library synthesis technique, binders to
individual proteins are selected by afﬁnity from complex
mixtures. Binding events are detected by harnessing the power
of high-throughput sequencing to identify DNA tags encoding
the bound chemotypes. Chemotypes of interest can then be re-
synthesized off-DNA for assay testing and further development.
The technology has become widely used throughout the
pharmaceutical, biotech and academic environments to discover
ligands and is continually evolving25–27. ELT has been employed
successfully to identify numerous molecules that bind to proteins
from diverse target classes and sample deep chemical space as
well as understand structure activity relationships directly from
the screening output28–38.
At GlaxoSmithKline (GSK), we have created a DNA-encoded
compound collection containing over 100 different libraries
comprised of billions of unique molecules generated from over 40
reaction types using a split and pool encoding strategy39,40. These
libraries are ultimately assembled and screened in a single pool,
allowing for the rapid identiﬁcation of chemical ligands. The
technology has continued to mature and ELT is now considered
for every small molecule screening effort in the GSK portfolio to
discover new chemical matter. As high-throughput sequencing
has continued to advance and we have reﬁned our analysis
methods, the target capacity of the technology has increased.
Pairing these improvements with the automation of protein
immobilization and afﬁnity selections has allowed for the
screening of multiple targets in a single experiment, as opposed
to probing one target at a time, enabling a panel to be executed in
a 5–7-month period41. Thus, the interrogation of a larger fraction
of the proteome is possible while maintaining the simplicity and
efﬁciency of a reductionist target-based approach.
Here we present the successful use of this strategy to identify
tractable targets from Staphylococcus aureus and Acinetobacter
baumannii and to discover individual lead/tool molecules for
six different target proteins. We describe the chemical series
and their activity against each protein. In addition, we propose
an evolution of the panel screening, in which the output of the
screen moves beyond identifying active pharmacophores and is
used to rapidly assess targets based on their ligandability as
determined by ELT. The reﬁned approach was used to prioritize
proteins from Mycobacterium tuberculosis and we present those
results along with active pharmacophores against one of the
highest-ranked targets as a proof of concept. Our results
demonstrate that ELT can inform the allocation of resources
within the drug discovery process towards the most chemically
tractable targets. We envision the methodology will provide a
tool to assess targets associated with virtually any therapeutic
area. Parallel screening could include targets clustered in
pathways, related targets, or a single target examined under
multiple conditions perhaps using multiple constructs42,43.
While this assessment is independent from target selection in
the broader biological context, the technique could enable a
deeper understanding of disease biology by rapidly providing
much-needed tool molecules18,44,45. Here we report data
supporting this assertion as well as several novel chemotypes
as tools for the antibacterial ﬁeld.
Results
ELT selection outcome. A schematic showing the streamlined
selection of targets for R&D efforts through the ELT tractability
approach is illustrated in Fig. 1. The ELT selections were con-
ducted by immobilizing afﬁnity-tagged protein onto an afﬁnity
matrix, then exposing the protein to pooled compound libraries
before washing away non-binders and recovering bound com-
pounds by heat elution (detail below). This process was repeated
to enrich bound species and reduce the population that does not
bind to the protein of interest (described previously)20,31–33,37.
The individual selection process was adapted to an automation
platform such that hundreds of proteins could be evaluated in
parallel. For each selection, ﬁnal yields of 107–109 sequences of
DNA were obtained, quantiﬁed using qPCR and ampliﬁed for
sequencing as described in the ‘Methods’ section and
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previously20. The collected data were translated from the DNA
barcode to the associated encoded molecule. On the basis of the
library size and the number of sequences obtained, the noise level
was calculated for each selection. Signal strength is reported as a
value relative to that level (that is, signal value of 10 represents
10-fold greater measurement than noise). All data points with
signal greater than two were included in subsequent data analysis
steps. This output was then ﬁltered to remove chemotypes that
had been identiﬁed as binders to afﬁnity matrix or multiple
proteins in past selections (non-speciﬁc or frequent nuisance
binders). This set of speciﬁc binders was clustered by chemical
similarity (Tanimoto score40.85) or shared building blocks. The
compounds can be used as tools to assess the validity of the target
or potentially as a lead molecule. Over the course of these panels,
the number of libraries available for ELT screening expanded
from 36 in the initial panel to 84 in the ﬁnal screening panel and
is currently over 100. This increase in library size was
accompanied by a parallel increase in the reaction types used to
create those libraries contributing to a modest increase in
diversity and an ability to probe a greater breadth of chemical
space. Generally, we assessed the target’s tractability by examining
the number of enriched chemical series as illustrated in Fig. 2 by a
plot of the number of binders versus target protein. Committing
chemistry resource to the most tractable targets ﬁrst, clusters with
dense representation, high signal strength and favourable
chemical properties were prioritized for synthesis of
Ligandability
assessment
Binding
confirmation
Hundreds of proteins
screened against trillions
of compounds 
Targets with ELT signal
Prioritized targets
Off-DNA synthesis
Discovery of
active series
Enable therapeutic
programmes
Opportunity
Hits/leads
Tools/probes
Targets broadly associated with disease
Partially validated proteins
Novel targets with unknown ligandability
Any tagged proteins
Figure 1 | Schematic representation of the ELT screening and ligandability assessment strategy. Hundreds of potential targets of interest are
immobilized and screened against GSK’s DNA encoded libraries. Targets with signal are ranked by the counts of ELT binders which correlate to the protein’s
chemical ligandability. Data is used to plan off-DNA synthesis and conﬁrm hits in assays. In addition to novel chemical starting points for lead optimization,
the output is a target/chemotype pair that enables therapeutic programs by providing tools for target validation as well as a ranking of targets to prioritize
further studies.
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representative chemical series46. In addition, a structure similarity
search (Tanimoto 40.85) was conducted against the corporate
collection for every target, including those with fewer binders,
enabling rapid hit conﬁrmation as well as interrogation of all
targets with signal. Speciﬁc outcomes for each of the three panels
are described below.
S. aureus panel. The S. aureus ELT target panel was a collection
of 39 essential enzyme targets. Table 1 shows the high-level
progression of the targets in each panel; for detailed target
information, see Supplementary Table 1. These targets were
selected based on their potential utility as antibacterial drug tar-
gets and the availability of a biochemical assay system either
inside GSK or rapidly adaptable from reported literature. N- and
C-terminal dual-tagged proteins were subjected to ELT selections;
one tag was used for rapid protein puriﬁcation and the second for
ELT selection immobilization. Miniaturization, automation and
coupling of the puriﬁcation and ELT selections in a parallel
method enabled maximum efﬁciency (described in detail in
Supplementary Methods). Data from the targets were examined
individually and chemical series for 14 targets were chosen for
follow-up by off-DNA synthesis (Fig. 2a). Approximately ﬁve
compounds per chemical series and three chemical series for each
target were synthesized for activity testing in biochemical assays.
Following this conﬁrmation, the activity of the compounds was
assessed by cellular toxicity assays as described in the ‘Methods’
section. After compound synthesis and in vitro testing, seven
targets gave at least one chemical series with conﬁrmed bio-
chemical activity measured with a minimum of two replicates, see
Supplementary Table 1. This represents an attrition rate of
roughly 50%, which is consistent with our previous ELT screening
experience at GSK. Antibacterial activity was demonstrated
against S. aureus for several chemical series identiﬁed from ﬁve
targets, methionyl-tRNA synthetase (MRS), isoleucyl-tRNA syn-
thetase (IRS), methionine aminopeptidase (MetAP), undecapre-
nyl pyrophosphate synthase (UppS) and acetyl-CoA carboxylase
(ACC). The S. aureus UppS ELT hit series, its medicinal chem-
istry efforts, X-ray co-crystal structure and genetic and bio-
chemical conﬁrmation of antibacterial MoA were recently
reported in a separate publication47. Similarly, the acetyl-CoA
carboxylase hit series and characterization studies will be
published at a later time. See Supplementary Methods for more
details on compound characterization.
In Table 2, we disclose a representative novel MRS inhibitor
belonging to a phenylbenzimidazole chemical series. It has potent
enzyme activity in an MRS biochemical assay with an IC50 of
830 pM and possesses moderate antibacterial activity with a
minimum inhibitory concentration (MIC) value of 0.5 mgml 1
against S. aureus. Importantly, we conducted studies that suggest
the cellular activity of the compound was linked to the inhibition
of MRS. Increasing the levels of MRS in an overexpressing strain
resulted in a higher MIC. We observed that benzimidazole 1 gave
a signiﬁcant MIC increase of 8-fold (uninduced) and 4128-fold
(induced with 0.1 mgml 1 anhydrotetracycline) as compared to a
vector control strain. These studies were conducted with a
minimum of two replicates. In contrast, we were unable to
observe the on-target antibacterial activity of the IRS inhibitor
represented by the t-butylphenyl-piperazine amide 2 shown in
Table 2. We include this series as an example of a hit that binds
and inhibits its selected target but whose antibacterial activity
could not be established as on-target. An exemplar from a MetAP
benzimidazole series is shown (benzimidazole-triazole 3) with an
IC50 of 0.35 mM in the biochemical assay (described in
Supplementary Methods) but lacks antibacterial activity, hence
its antibacterial MoA could not be conﬁrmed in overexpression
studies.
M. tuberculosis
EchA6
FbpA
KasA
Pks13
LpdC
FbpC
DHFR
MabR
AccD4
AccD6
AccA3
PtpA
PtpB
DXR
AccD5
AftA
AspS
GlfT2
Rv3267
GlmU
MurI
TopA
PanC
InhA
FasR
TrxC
MetAP
PknB
0 2,000 4,000 6,000 8,00010,000
High priority
Medium priority
Low priority
bA. baumanii
0 2,000 4,000 6,000
Found series with MIC + MoA
Found series with MIC
No active series found
Binder count
S. aureus
UppS
MRS
ACC
Pth
IRS
MetAP
PyrH
NRS
AcpS
PPAT
WRS
HRS
MurA
KRS
0 100 200 300
a
Found series with IC50
No active series found
Ta
rg
et
UppS
LpxA
LolA
Dxr
LpxD
FabZ
LpxH
IspF
CCA
FtsI
ThyA
Pth
IspG
MrcB
PbpA
MurG
BirA
Dxs
AcpP
*
Figure 2 | Count of binders that are speciﬁc to each target. (a) Results of screening against S. aureus and A. baumanii panels. Targets are binned and
coloured by the activity of molecules found for the target and sorted by the number of binders. (b) Proposed priority of targets for the M. tuberculosis panel.
Targets are sorted by binder count and coloured by the proposed priority based on the number of speciﬁc binders found. *Compounds for Dxr conﬁrmed by
biochemical assay.
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A. baumannii panel. On the basis of our experience with the S.
aureus campaign, we decided to expand the number of targets
examined from the A. baumannii genome as a representative
organism for the discovery of novel Gram-negative agents. To
further simplify the process, we tested the antibacterial activity of
all synthesized compounds against a panel of bacterial strains as
shown in Supplementary Table 2. This eliminated the need to
develop biochemical assays for each target and focused the effort
on agents with cell penetration. Eighty proteins were selected for
screening from the A. baumannii genome and, similar to the
S. aureus panel described above, constructs were generated
incorporating dual afﬁnity tags (streptavidin-binding peptide and
FLAG tag). E. coli was again used as a heterologous expression
host and cell pellets, conﬁrmed to be expressing protein, were
thawed on the day of selection and lysed (described in
Supplementary Methods). Each target protein was puriﬁed using
streptavidin agarose resin, eluted with biotin and quantiﬁed using
an Agilent Bioanalyzer all on the same day as the selection
experiment. This removed the need for large-scale protein pre-
parations to be conducted and removed a freeze/thaw cycle that
can often compromise the quality of the reagent. Of the 80 tar-
gets, 70 were successfully puriﬁed using this rapid process. Our
panel screen gave positive ELT selection signal for 52 targets and
18 were prioritized for off-DNA synthesis. After off-DNA
synthesis of 3–5 chemical series per target and/or similarity
searching of the GSK compound collection, 17 of the targets had
at least one chemical series with activity in the antibacterial MIC
assay panel and 3 targets had compounds that show positive MoA
data. We disclose three chemical series identiﬁed from these
targets with conﬁrmed on-target activity shown in Table 2. LpxA,
involved in lipid A biosynthesis, yielded two chemotypes with
multiple compounds showing on-target activity. We show a
general structure of a chemical series for one of the LpxA che-
motypes and a particular aryl-urea series 4 with conﬁrmed on-
target MoA. UppS from A. baumannii was again found to pro-
duce a high number of binders and three unique series with
positive MoA were identiﬁed, one of these (compound 5) is
shown in Table 2. LolA, a lipoprotein chaperone, afforded a
chemical series with positive MoA with a disclosed tetra-
hydropyrido-pyrimidine exemplar 6 shown in Table 2. See the
Supplementary Methods for additional details on compound
characterization, assay methods and activity results across a panel
of bacteria.
M. tuberculosis panel. Having seen the ability of these panels to
rapidly ﬁnd ligands for a diverse set of protein targets, we pro-
posed using the number of ELT binders to rank the tractability of
proteins from M. tuberculosis. An additional goal of this screen
was to obtain tool molecules that could help validate a target as
pharmacologically relevant. We did not place any requirements
for target inclusion other than that the protein had to be puriﬁed
and contain either a 6-histidine or biotin afﬁnity tag. We obtained
a diverse group of targets from academic collaborators for ELT
screening. Eleven academic partners provided 42 protein pre-
parations for screening (Supplementary Table 1). Although little
to no previous information existed on the chemical tractability for
most of these 42 proteins, a small number of known, chemically
tractable targets were included as ‘controls’ (for example, InhA
and DHFR). The ranking of target tractability is shown in Fig. 2b.
Twenty-seven out of 42 targets afforded enriched chemotypes,
and 13 targets with a greater number of binders were selected for
further data analysis. Each of these targets produced multiple
chemical series, and we chose three–ﬁve chemotypes for synthesis
and off-DNA evaluation. The synthesized compounds 7–9
(Table 2) were easily assayed in a biochemical assay from the
reported literature and we disclose three distinct chemical series
with potency varying from 492 nM to 4.9 mM against dfrA (also
known as DHFR). Compounds 7–9 were active against
M. tuberculosis and the MIC values, measured in duplicate, are
reported in Table 2. Although inhibitors of DHFR are already
widely known, the mixture of familiar (compound 8 has a similar
substructure to the known DHFR inhibitor methotrexate) and
novel inhibitor chemotypes (7 and 9) identiﬁed by the ELT
selection serves to validate the platform and demonstrate its
powerful potential. InhA, the enoyl reductase targeted by the
frontline therapeutic isoniazid, was screened but did not result in
hits (see ‘Discussion’ section). Assessment of the compounds
synthesized for other targets remains ongoing, with chemical
series against four targets, KasA, LpdC, DHFR and DXR, con-
ﬁrmed in biochemical assays to date.
Discussion
Tools to prioritize the abundance of uncharacterized proteins that
will serve as the next generation of drug targets are crucial to the
successful development of new medicines. The ELT target panel
platform described here provides an opportunity to select protein
targets based on an experimental and data-driven ligandability
assessment. Starting with a diverse set of proteins that are of
interest to a particular therapy area, the strategy rapidly identiﬁes
tractable targets and simultaneously deﬁnes novel starting points
for therapeutic programme teams to explore. To our knowledge,
no other report provides an experimental approach to tractability
assessment that can evaluate a large set of proteins de novo in
such a short period of time15,17.
Initially, the concept of screening many targets in parallel was
proposed as a way to simply identify novel chemical matter for
antibacterial drug discovery with less investment of both time and
effort. The dual tagging, automation and miniaturization
Table 1 | ELT screening progression.
Phase S. aureus A. baumannii M. tuberculosis
Ligandability assessment
Initial number of targets considered 39 80 42
Targets amenable to ELT selection 32 70 41
Targets with ELT signal 14 52 27
Binding conﬁrmation
Targets with off-DNA synthesis 14 18 13
Targets with conﬁrmed active chemical series (IC50 and/or MIC) 7 17 4*
Targets with conﬁrmed MoA 2 3 ND
ND, not determined.
The table shows a summary of the progression of protein targets through each tractability panel. For additional detail and a full list of targets prosecuted, see Supplementary Table 1.
*Off-DNA activity assessment ongoing for remaining nine targets.
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Table 2 | Representative chemical series discovered in three tractability campaigns.
Campaign Target Compound Scaffold Exemplar
IC50
(µM) 
MIC*
(µg ml–1)
S. aureus
MRS 
R2 O
O
HO
Br
R3
R1
R4
NH
NH
N
N
N
H
N
H
N
O
H
R1
R1
R1
R1
R1
O
N
N
H
S
O
N
H
O
O
N
N
NH
R2
R2
Cl
O
O O
N
N
Cl
Cl
Cl N
N
O
Cl N
N
N
N
N
N
O
O
O
O
O
O
O
Cl
Cl
HN
HN
N
N
N
N
N
HN
N
F
F
HN
Cl
Cl
O
O
H
N
H
N
H
N
H
N
H
N
H
N
N
N
N
NHN
O
O
O
HN
O
0.00083 
± 
0.00005
0.5 Y
IRS 0.75 ± 0.21 4 N
MetAP  0.35 ± 0.01 > 128 ND
A. baumannii
LpxA ND >64 Y
UppS  0.043 ± 0.025 >128 Y
LolA  ND >128 Y
M. tuberculosis
DHFR  
0.492 ± 
0.004 80
† ND 
N N NH
N
NN
O
O
O
O
N
H
N
H
NH2
NH
O
O
O O
O
O O
O
NS
H
N
H
N
N
OH2N
OH
O O
O
O
O
O
NS
H
N
H
N
N
R1
R2
O
N N
N
NH2
NH2
NH
O
R1
R1 OH
0.61 ± 
0.42 2.5
† ND
1 
2 
3 
4
5 
6 
7 
8 
9 4.9 ± 2.2 80
† ND
MoA
ND, not determined; MoA, mode of action.
The scaffold column represents the selected pharmacophore with areas of substitution indicated by R. All data are reported for the single exemplar shown. IC50 values are reported as the average of two
replicate experiments with s.d. values calculated using the n 1 method.
*Minimum inhibitory concentration measured against S. aureus WCUH29 wild type or A. baumannii BM652 efﬂux strains for S. aureus or A. baumannii campaigns with a minimum of two independent
experiments.
wMIC unit is in mM and is determined against M. tuberculosis H37Rv.
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strategies described in the ‘Methods’ section (and previously)
enabled the puriﬁcation and screening of multiple targets in a
single experiment41. We screened 39 proteins from S. aureus in
the ﬁrst panel, utilizing 36 libraries combined in a single pool,
highlighting 14 tractable targets and, with limited chemistry
investment, we discovered active chemical series for seven of the
targets. Building on the success of the S. aureus panel, we initiated
a reﬁned strategy against a panel of protein targets from the
Gram-negative pathogen A. baumannii. While most of these
targets are essential for growth to the bacteria, some targets were
added in this iteration, like LpxA, that are non-essential for
A. baumannii. These are of interest to Gram-negative discovery
projects in general as they are essential in most other Gram-
negative pathogens and show severe growth impairment in
A. baumannii when knocked out48. To rapidly identify potential
lead compounds as well as explore a wider set of targets, we
directly measured MIC, rather than developing individual
biochemical assays for each target. Thus, the ability of hits to
overcome bacterial permeability was added as a ﬁlter. This
reﬁnement increased the number of targets available for screening
since no biochemical assay development was needed. However,
the lack of biochemical data reduced our ability to conﬁrm the
activity of every chemotype as a tool rather than a cell penetrant
lead. We observed active compounds by MIC testing, with hits
from 17 of 18 targets showing activity against A. baumannii. Due
to resource constraints and the focus of the therapeutic
programme, only 3 of the 17 hits were fully characterized in
mechanistic studies and are reported here.
By applying ELT screening to the antibacterial panels, we were
able to rapidly interrogate 102 targets and discover active chemical
matter against 24, a success rate of 24%. A similar rate of success for
ﬁnding hits from high-throughput screening (HTS) against
antibacterial targets has been reported earlier by GSK49. Indeed,
the relatively low success in HTS along with the time required for
lead molecule development as well as regulatory and commercial
concerns are cited as reasons why many large pharmaceutical
companies have abandoned this therapeutic area50. A comparison
of 29 S. aureus targets common to both HTS and ELT approaches
showed that in 21 of the 29 HTS campaigns, our ELT strategy
would have predicted the outcomes (summarized in Table 3; for
details, see Supplementary Table 3). In addition, for the remaining
eight targets, the ELT screen successfully found hits for ﬁve targets
where HTS did not. Another beneﬁt of the ELT parallel screening
method is that signiﬁcantly less resources and time are needed to
screen the collection of targets when compared to HTS. The time
required to proceed from the set of puriﬁed proteins to an analysis
of the chemical output averaged 3–4 months with an additional 2–3
months of time committed to chemical synthesis and activity
testing. HTS assay development through hit analysis and hit
qualiﬁcation happens on a similar timescale (9–12 months).
However, while only a single target is probed in HTS, here we
describe a parallel ELT strategy that can interrogate many proteins
in the same timeframe using only microgram amounts of reagent
and far less human resource.
We hypothesized that applying chemistry resource to only the
targets with the greatest number of binders would further
improve the screening efﬁciency. The relationship between the
ELT output and success in discovering active chemical series is
illustrated by Fig. 2a. Here we have binned targets by outcome
and ordered by the number of binders, ﬁnding that the successful
targets were those with a greater number of binders. In the
S. aureus panel, 7 of 14 highly ranked targets were conﬁrmed as
active and in the A. baumannii panel, three prioritized targets
yielded compounds with conﬁrmed MoA. The ﬁnding that ELT
could rapidly winnow down a diverse set of targets and highlight
those that were chemically ligandable provided an opportunity to
improve our decision making and prioritize resources onto the
most tractable targets. Utilizing the output of the ELT selections
to predict downstream target success, both time and money can
be saved while simultaneously identifying novel chemical starting
points. We therefore hypothesize that ELT panels can addition-
ally be used for pure tractability assessments for any group of
interesting targets.
This was explored in a third panel by screening against
M. tuberculosis proteins. As focus shifted from the identiﬁcation
of new chemical matter to tractability assessment, we chose to
screen only against high-quality puriﬁed protein. The beneﬁt of
this can be seen in the reduced attrition of targets entering
selection, with 41 of 42 proteins being amenable to ELT at the
selection stage (Table 1 and Supplementary Table 1). Targets were
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Figure 3 | Representative data set of enriched binders for the M. tuberculosis target DHFR. The average molecular weight of clustered chemotypes is
plotted versus average cLogP. Clusters are sized by the number of members and coloured by maximum signal strength. Chemical series with active
molecules are indicated by their scaffolds.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16081 ARTICLE
NATURE COMMUNICATIONS | 8:16081 | DOI: 10.1038/ncomms16081 | www.nature.com/naturecommunications 7
ranked by decreasing number of binders (Fig. 2b). Active
chemical matter for three high-priority targets (DHFR, KasA
and LpdC) and one medium-priority target (DXR) has been
conﬁrmed, and chemotypes for the nine remaining targets are
currently being evaluated. The effects of reﬁnements and
advances in the ELT process and data analysis are evident when
comparing the panels shown in Fig. 2, which illustrates increases
in both the number of binders found and number of targets with
signal. This increased information density enabled the ranking of
targets by tractability, allowed for improved discrimination
between targets and facilitated better decision making.
The challenges in interpreting data and planning chemical
synthesis have been met by advances in analysis tools and
streamlining the planning of chemical synthesis. Historically, we
examined an individual library through cube analysis to provide
guidance for off-DNA hit to lead efforts30–33,35,37,51. Figure 3
shows a representative data set for a single target, DHFR, where
chemical clusters are plotted with their average molecular weight
versus the average cLogP. This is a common representation of the
data that allows for rapid comparison of chemical series by signal
intensity and also by physicochemical properties. Chemical series
with higher signal intensity and larger cluster size that also fell
into more attractive physicochemical space were selected for
follow-up46. All targets were evaluated in parallel and common
chemical reactions were executed in a concerted manner to
increase efﬁciency. Representatives from each of the highlighted
chemical series were then synthesized off-DNA and tested in
biochemical or cellular assays. Additional visualizations were
generated to examine potential structure activity
relationships37,51. The structure activity relationships analysed
within each chemical cluster allows for rapid pharmacophore
identiﬁcation and expansion of a single hit into a chemical series.
A key component of our strategy is that attrition is expected
and that a negative result is not predictive, it simply helps focus
on success at each step. It should be emphasized that we aim to
expand the possibility of discovery to a wider range of targets and
then redirect focus onto ligandable targets with speed and
efﬁciency and do not advocate ignoring difﬁcult targets. It is also
important to note that targets with fewer ELT binders under our
screening conditions may in fact be highly tractable under
different conditions. InhA, the target of tuberculosis drug
isoniazid, was found to have low tractability despite having
known ligands. This enzyme is known to require cofactor to bind
inhibitors and has an active site loop that plays a critical role in
inhibition52–54. Recent publications report ELT selections for
InhA consistent with the notion that the presence of cofactor
improves this target’s tractability33,42. In fact, the method
described here could be used to test the same target under
many conditions or multiple constructs of the same target for
optimization. These conditions may inﬂuence the stability of the
protein or the conformation of the active site, which will impact
the outcome of the ELT selection. Previous reports have focused
on the discovery of ligands speciﬁc for protein conformations or
complexes, either by screening in the presence of cofactors or
against homologous proteins and our technique can be easily
adapted for similar screens against any group of proteins to
produce a relevant ranking33,42,55.
The ELT screening campaigns presented here have successfully
identiﬁed multiple antibacterial compounds with conﬁrmed MoA
and have led to multiple lead optimization programmes. We have
also applied this principle to other novel target areas, such as
deubiquitinases, methyl readers, bromodomains and histone
methyltransferases, and current studies are underway to include
additional target areas (for example, the kinome), expanding the
potential impact of this strategy. In cases where modulation of
many targets converges on a single disease or phenotype, we are
designing ELT panels where all of the off-DNA synthesis
converges on a single phenotypic assay. The result will be a
tractability ranking for all of the targets connected to a particular
disease state along with potential tool and lead molecules to
further explore the biology. Given the highly competitive,
challenging and expensive endeavour of drug discovery, it is
crucial to focus resource where it is most likely to have a positive
impact. Our strategy enables teams to quickly identify targets to
focus on and we see tremendous potential for this approach to
impact other areas throughout the R&D community.
Methods
Just-in-time protein puriﬁcation. E. coli cell culture expressing target protein was
stored as a frozen pellet until the day of selections. Approximately 200mg of cell
pellet was dissolved in B-PER cell lysis solution (Thermo 90084) and incubated at
room temperature for 20min with occasional stirring. Solutions were divided
evenly into eppendorf tubes and centrifuged at 18,000 g, 4 C for 20min. A 10ml
ﬁlter spin column (Pierce 89898) was prepared for each sample. The column was
loaded with 400 ml volume of 50% slurry of Streptavidin Ultra-link Resin (Peirce
53114). Solution was allowed to ﬂow through and 5ml of ELT buffer (50mM Tris-
HCl pH 7.5, 0.15M NaCl, 0.1% Tween 20) was added to equilibrate resin bed. The
resin was centrifuged for 3min at 500 r.p.m., the column capped and 100 ml of
buffer added to keep the resin moist. A measure of 3ml of clariﬁed cell lysate was
loaded onto the prepared resin bed and incubated on ice for 15–20min. The
solution was allowed to ﬂow through the column and centrifuged for 3min at
500 r.p.m.. A measure of 10ml of ELT buffer was loaded to wash the resin and
centrifuged for 3min at 500 r.p.m.. A measure of 500 ml of 2.5mM D-biotin was
added (Sigma B-4501). To make this stock solution solid, D-biotin was dissolved to
0.5M in 1M NaOH, diluted to 2.5mM with ELT buffer and incubated on ice for
45min with gentle and occasional stirring. Column was transferred to a clean tube
(Falcon) and eluted by centrifugation at 500 r.p.m. for 3min. Puriﬁed proteins were
quantiﬁed using a Bioanalyzer (Agilent 230 Protein Chip Kit, Fisher NC9415734)
where purity and approximate concentrations were accessed. A yield of 30–200 mg
of target protein was observed with purity varying from B60 to 495%.
Encoded library preparation for selection. ELT libraries were combined into a
pooled library for screening purposes. For each screening effort, the then available
libraries were ligated to contain a unique library identiﬁer and then combined into
an equimolar mixture at a concentration of 0.5mM. After ﬁnal library closing to
add a pool identiﬁcation sequence, these libraries could then be identiﬁed as
associated with each individual condition after sequencing (see Supplementary
Methods).
PhyNexus tip preparation and automated selections. Each condition was
screened using a Beckman Coulter, BioMek FX robot. Four 200 ml Phynexus tips
packed with 5 ml beds of either M2 anti-FLAG, IMAC or streptavidin resin were
employed per target and equilibrated before selections using ELT selection buffer
(50mM HEPES, pH 7.5, 300mM NaCl, 1mM CHAPS, 10mM imidazole,
0.1mgml 1 sheared salmon sperm DNA, 1mM MgCl2, 1mM CaCl2, 1mM
DTT). Tips were used within 2 h of equilibration. Ten nmoles of pooled library
were suspended in 100ml of selection buffer and used as input for each selection.
Ninety-six-well plates were prepared containing 10 mg of target protein suspended
in 110 ml of selection buffer per well in row A for each of four rounds of selection. A
measure of 110 ml selection buffer was pipetted per row into rows B–G to serve as
washes. In the case of streptavidin tips only, 1mM biotin was included in the wash
Table 3 | Consistency of HTS and ELT outcomes for 29 S. aureus targets.
ELT active ELT inactive
HTS active 4 3
HTS inactive 5 17
Comparison of target outcomes from ELTand HTS where the same target was screened by both methods. ELTand HTS outcomes agreed in 21 of 29 campaigns. For the remaining eight targets, ELT found
hits for ﬁve where HTS did not.
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buffer in row B to reduce enrichment of streptavidin binders. In addition, 120 ml of
selection buffer in row H was used for heat elution. A BioMek FX protocol was
developed in which puriﬁed protein from row A was captured for 15min on
Phynexus tips, washed once with selection buffer from row B, exposed to library
pool for 30min, washed ﬁve times with selection buffer (rows C–G) and heat eluted
in selection buffer from row H at 90 C to recover binders. Four rounds of selection
were performed in this manner with the output of each round carried forward as
the input to the successive round with fresh protein and new tips.
Selection output processing. Outputs of each selection condition were puriﬁed
using a Qiagen Qiacube running a nucleic acid puriﬁcation protocol and then
quantiﬁed by qPCR run on a Roche Lightcycler. Total DNA output ranged from
2 107 to 1 109 copies, and was PCR ampliﬁed with primers adaptors to add
sequences compatible with Illumina sequencing ﬂowcells. PCR output was puriﬁed
using Agencourt AMPure XP SPRI beads according to the manufacturer’s
instructions and then quantitated on an Agilent BioAnalyzer using a high sensi-
tivity DNA kit. Final concentration of amplicon for each sample was between 2 and
40 nM. Portions of products were loaded to generate B20 million clusters
per selection condition on an Illumina GAII or HiSeq platform.
Sequencing and data analysis. Libraries were pooled in equal volume and each
library had a unique DNA tag that enabled sequence deconvolution. Each warhead
was uniquely tagged with a speciﬁc DNA tag combination (described previously20)
and also included a degenerate region to account for sequencing or ampliﬁcation
artifacts. Compounds with identical degenerate regions were counted as a single
occurrence.
For every library and for each target, the total number of unique warhead
sequences was counted. Compounds were then grouped by the different possible
combinations of building blocks (for example, single cycle ‘mono’ synthons, two
cycle ‘di’ synthons and so on). The total count for every combination was then used
to calculate signal as the fold value of number of copies divided by the expected
noise level (as deﬁned by the theoretical distribution of copies). Every chemotype
with a signal value 42 was reported. All chemotypes with signal were compared
against a database of historic target. Any chemotypes that also had signal against a
historic target were ﬂagged as promiscuous and removed from further
consideration. Any chemotype with signal against empty matrix (no-target control)
was similarly removed. Of the remaining chemotypes, only those that had signal
against a single target from the panel were considered for ﬁnal evaluation, except in
cases where the target had highly similar binding pockets, substrates or cofactors.
A data table was created containing all chemotypes and their associated signal
values for each target/library combination. These data were graphed in Spotﬁre and
used to rank the targets by total number of chemotypes. To prioritize off-DNA
follow-up synthesis, chemotypes with signal were clustered together based on
calculated Tanimoto similarity by two-dimensional ﬁngerprints. Clusters with high
representation and favourable physical chemical properties (lower average
molecular weight, lower average cLogP) were chosen for further evaluation and off-
DNA chemistry planning.
Data availability. All relevant data are available from the authors on request.
References
1. Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the
decline in pharmaceutical R&D efﬁciency. Nat. Rev. Drug Discov. 11, 191–200
(2012).
2. Smietana, K., Ekstrom, L., Jeffery, B. & Moller, M. Improving R&D
productivity. Nat. Rev. Drug Discov. 14, 455–456 (2015).
3. Hann, M. M. & Keseru, G. M. Finding the sweet spot: the role of nature and
nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11, 355–365 (2012).
4. Russ, A. P. & Lampel, S. The druggable genome: an update. Drug Discov. Today
10, 1607–1610 (2005).
5. Mullard, A. The phenotypic screening pendulum swings. Nat. Rev. Drug
Discov. 14, 807–809 (2015).
6. Dominguez, E. et al. Integrated phenotypic and activity-based proﬁling links
Ces3 to obesity and diabetes. Nat. Chem. Biol. 10, 113–121 (2014).
7. Forsyth, R. A. et al. A genome-wide strategy for the identiﬁcation of essential
genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387–1400 (2002).
8. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era.
Nature 529, 336–343 (2016).
9. Hopkins, A. L. et al. Rapid analysis of pharmacology for infectious diseases.
Curr. Top. Med. Chem. 11, 1292–1300 (2011).
10. Edwards, A. M. et al. Too many roads not taken. Nature 470, 163–165 (2011).
11. Hajduk, P. J., Huth, J. R. & Tse, C. Predicting protein druggability. Drug Discov.
Today 10, 1675–1682 (2005).
12. Egner, U. & Hillig, R. C. A structural biology view of target drugability. Expert
Opin. Drug Discov. 3, 391–401 (2008).
13. Kutilek, V. D. et al. Integration of afﬁnity selection-mass spectrometry and
functional cell-based assays to rapidly triage druggable target space within the
NF-kappaB pathway. J. Biomol. Screen. 21, 608–619 (2016).
14. Hajduk, P. J., Huth, J. R. & Fesik, S. W. Druggability indices for protein targets
derived from NMR-based screening data. J. Med. Chem. 48, 2518–2525 (2005).
15. Edfeldt, F. N., Folmer, R. H. & Breeze, A. L. Fragment screening to predict
druggability (ligandability) and lead discovery success. Drug Discov. Today 16,
284–287 (2011).
16. Ward, R. A. Using protein-ligand docking to assess the chemical tractability of
inhibiting a protein target. J. Mol. Model. 16, 1833–1843 (2010).
17. Perola, E., Herman, L. & Weiss, J. Development of a rule-based method for
the assessment of protein druggability. J. Chem. Inf. Model. 52, 1027–1038 (2012).
18. Salamon, H., Klika Skopic, M., Jung, K., Bugain, O. & Brunschweiger, A.
Chemical biology probes from advanced DNA-encoded libraries. ACS Chem.
Biol. 11, 296–307 (2016).
19. Brenner, S. & Lerner, R. A. Encoded combinatorial chemistry. Proc. Natl Acad.
Sci. USA 89, 5381–5383 (1992).
20. Clark, M. A. et al. Design, synthesis and selection of DNA-encoded small-
molecule libraries. Nat. Chem. Biol. 5, 647–654 (2009).
21. Kleiner, R. E., Dumelin, C. E. & Liu, D. R. Small-molecule discovery
from DNA-encoded chemical libraries. Chem. Soc. Rev. 40, 5707–5717
(2011).
22. Gartner, Z. J. & Liu, D. R. The generality of DNA-templated synthesis as a basis
for evolving non-natural small molecules. J. Am. Chem. Soc. 123, 6961–6963
(2001).
23. Hansen, M. H. et al. A yoctoliter-scale DNA reactor for small-molecule
evolution. J. Am. Chem. Soc. 131, 1322–1327 (2009).
24. Melkko, S., Scheuermann, J., Dumelin, C. E. & Neri, D. Encoded self-
assembling chemical libraries. Nat. Biotechnol. 22, 568–574 (2004).
25. Mullard, A. DNA tags help the hunt for drugs. Nature 530, 367–369 (2016).
26. Yuen, L. H. & Franzini, R. Achievements, challenges, and opportunities in
DNA-encoded library research: an academic point of view. Chembiochem 18,
1–9 (2016).
27. Lerner, R. A. & Brenner, S. DNA-encoded compound libraries as open source: a
powerful pathway to new drugs. Angew. Chem. Int. Ed. Engl. 56, 1164–1165
(2017).
28. Southan, C., Varkonyi, P., Boppana, K., Jagarlapudi, S. A. & Muresan, S.
Tracking 20 years of compound-to-target output from literature and patents.
PLoS ONE 8, e77142 (2013).
29. Gilmartin, A. G. et al. Allosteric Wip1 phosphatase inhibition through ﬂap-
subdomain interaction. Nat. Chem. Biol. 10, 181–187 (2014).
30. Yang, H. et al. Discovery of a potent class of PI3Kalpha inhibitors with unique
binding mode via encoded library technology (ELT). ACS Med. Chem. Lett. 6,
531–536 (2015).
31. Deng, H. et al. Discovery of highly potent and selective small molecule
ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded
library technology (ELT). J. Med. Chem. 55, 7061–7079 (2012).
32. Disch, J. S. et al. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as
potent inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem. 56, 3666–3679
(2013).
33. Encinas, L. et al. Encoded library technology as a source of hits for the
discovery and lead optimization of a potent and selective class of bactericidal
direct inhibitors of Mycobacterium tuberculosis InhA. J. Med. Chem. 57,
1276–1288 (2014).
34. Gentile, G. et al. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-
3 inhibitors. Bioorg. Med. Chem. Lett. 22, 1989–1994 (2012).
35. Kollmann, C. S. et al. Application of encoded library technology (ELT) to a
protein-protein interaction target: discovery of a potent class of integrin
lymphocyte function-associated antigen 1 (LFA-1) antagonists. Bioorg. Med.
Chem. 22, 2353–2365 (2014).
36. Thalji, R. K. et al. Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides
as inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 23,
3584–3588 (2013).
37. Franzini, R. M. et al. Identiﬁcation of structure-activity relationships from
screening a structurally compact DNA-encoded chemical library. Angew.
Chem. Int. Ed. Engl. 54, 3927–3931 (2015).
38. Goodnow, Jr R. A., Dumelin, C. E. & Keefe, A. D. DNA-encoded chemistry:
enabling the deeper sampling of chemical space. Nat. Rev. Drug Discov. 16,
131–147 (2016).
39. Ding, Y. & Clark, M. A. Robust Suzuki-Miyaura cross-coupling on DNA-linked
substrates. ACS Comb. Sci. 17, 1–4 (2015).
40. Satz, A. L. et al. DNA compatible multistep synthesis and applications to DNA
encoded libraries. Bioconjug. Chem. 26, 1623–1632 (2015).
41. Decurtins, W. et al. Automated screening for small organic ligands using DNA-
encoded chemical libraries. Nat. Protoc. 11, 764–780 (2016).
42. Soutter, H. H. et al. Discovery of cofactor-speciﬁc, bactericidal Mycobacterium
tuberculosis InhA inhibitors using DNA-encoded library technology. Proc. Natl
Acad. Sci. USA 113, E7880–E7889 (2016).
43. Cuozzo, J. W. et al. Discovery of a potent BTK inhibitor with a novel binding
mode using parallel selections with a DNA-encoded chemical library.
Chembiochem 18, 1–9 (2017).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16081 ARTICLE
NATURE COMMUNICATIONS | 8:16081 | DOI: 10.1038/ncomms16081 | www.nature.com/naturecommunications 9
44. Newman, R. H. & Zhang, J. Small molecules and chemical tools at the interface.
Nat. Chem. Biol. 4, 382–386 (2008).
45. Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem.
Biol. 11, 536–541 (2015).
46. Bayliss, M. K. et al. Quality guidelines for oral drug candidates: dose, solubility
and lipophilicity. Drug Discov. Today 21, 1719–1727 (2016).
47. Concha, N. et al. Discovery and characterization of a CLass of pyrazole
inhibitors of bacterial undecaprenyl pyrophosphate synthase. J. Med. Chem. 59,
7299–7304 (2016).
48. Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated
by complete loss of lipopolysaccharide production. Antimicrob. Agents
Chemother. 54, 4971–4977 (2010).
49. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad
bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug
Discov. 6, 29–40 (2007).
50. Payne, D. J., Miller, L. F., Findlay, D., Anderson, J. & Marks, L. Time for a
change: addressing R&D and commercialization challenges for antibacterials.
Philos. Trans. R. Soc. Lond. B. Biol. Sci. 370, 20140086 (2015).
51. Deng, H. et al. Discovery, SAR, and X-ray binding mode study of BCATm
inhibitors from a novel DNA-encoded library. ACS Med. Chem. Lett. 6,
919–924 (2015).
52. Li, H. J. et al. A structural and energetic model for the slow-onset inhibition of
the Mycobacterium tuberculosis enoyl-ACP reductase InhA. ACS Chem. Biol.
9, 986–993 (2014).
53. Pan, P. et al. Time-dependent diaryl ether inhibitors of InhA: structure-activity
relationship studies of enzyme inhibition, antibacterial activity, and in vivo
efﬁcacy. ChemMedChem 9, 776–791 (2014).
54. Tonge, P. J., Kisker, C. & Slayden, R. A. Development of modern InhA
inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
Curr. Top. Med. Chem. 7, 489–498 (2007).
55. Franzini, R. M., Nauer, A., Scheuermann, J. & Neri, D. Interrogating
target-speciﬁcity by parallel screening of a DNA-encoded chemical library
against closely related proteins. Chem. Commun. 51, 8014–8016 (2015).
Acknowledgements
We gratefully acknowledge our collaborators for supplying the puriﬁed proteins used in
the Tuberculosis screen: Prof. Yuk-Ching Tse-Dinh, Prof. John Blanchard, Prof. Ruslana
Bryk, Prof. Carl Nathan, Prof. Courtney Aldrich, Prof. David Sherman, Prof. Yossef
Av-Gay, Prof. Matthias Wilmanns, Dr Stacey Southall, Dr Argyrides Argyrou, Prof.
Lluis Ribas and Prof. Hugo Gramajo. We thank the designers at The Moment for their
contributions to Fig. 1, Stacey Walsh for sequencing work and Stephen Bach for con-
tributions to the bamA MoA studies. We also thank Craig Volker and Jim Brown
for bioinformatic analysis and Allison L. Haigney for help with editing the manuscript.
Authors contributions
P.A.C., J.C., C.P.D., Y.D. and X.L. synthezied DNA-encoded libraries. C.A.M., P.F.C.,
J.H., L.B., G.S.B., D.B.-A., R.H.B., J.L., A.M.-L., S.M.S., L.M.S., C.P.D., D.H., A.J.P. and
J.W.G. selected targets for screening. C.A.M., C.S.K., K.E.L., X.B., D.B.-A., Q.L., A.M.-L.,
S.M.S., D.H., C.C.A.-M., A.J.P., J.W.G. and G.E. proposed and evolved the concept. K.I.,
T.L.G., Q.L., R.L., J.M., P.M., H.Q., A.T. and J.W. performed protein expression, cloning
and puriﬁcation. C.A.M., C.S.K., K.E.L., X.B., J.H., S.B., D.B.A., R.H.B., A.M.-L., C.P.,
C.B.P., C.P.D., C.C.A.-M., A.J.P., J.W.G. and G.E. deﬁned screening strategy and
supervised projects. C.A.M., C.S.K., E.N.G., Q.L., H.P.O.K., T.O.K., C.P., M.S.S., F.S.S.,
L.M.S. and J.Z. performed ELT selections. S.S.C., T.O.K., G.S.S., M.S.S., F.S.S. and J.Z. did
ampliﬁcation, DNA sequencing, data entry and analysis. C.A.M., C.S.K., X.B., K.E.L.,
R.H.B., D.T.F., T.L.G., B.W.K., B.X., G.Y., J.Z., M.S.S., J.A.M. and G.E. did selection data
analysis and off-DNA chemistry planning. X.B., R.H.B., A.C., H.D., J.D., J.W.D., D.T.F.,
T.L.G., B.W.K., Y.L., D.J.W., B.X., G.Y., J.Z. and G.E. did chemistry planing and com-
pound synthesis. P.F.C., J.H., A.E.C., L.M., K.R. and M.F.T. did assay development and
compound testing. W.P.J., C.R.K. and M.W. did compound puriﬁcation, HRMS and
NMR of ﬁnal compounds. C.A.M., C.S.K., K.E.L., X.B., P.F.C. and G.E. did article
write-up.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing interests: With the exception of G.S.B., all the other authors are either
currently or in past have been employees and stockholders of GlaxoSmithKline.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Machutta, C. A. & Kollmann, C. S. et al. Prioritizing multiple
therapeutic targets in parallel using automated DNA-encoded library screening.
Nat. Commun. 8, 16081 doi: 10.1038/ncomms16081 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/
r The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16081
10 NATURE COMMUNICATIONS | 8:16081 | DOI: 10.1038/ncomms16081 | www.nature.com/naturecommunications
